IMS Novel Immune Therapies Educational Workshop Series
Are you a hematologist or oncologist treating patients with multiple myeloma? If so, this half-day workshop is for you.
The International Myeloma Society is pleased to announce the launch of its half-day Novel Immune Therapies Educational Workshop being held in convenient locations across the globe in 2022.
The treatment of multiple myeloma has dramatically evolved in recent years with immune-based strategies resulting in a very high impact in the relapsed refractory setting. Several targets are being evaluated, but B cell maturation antigen (BCMA) has proven to result in high response rates with excellent duration of responses in a very heavily pretreated patient population. Given the plethora of different drug products in this space, including antibody-drug conjugates, T cell engagers and CAR T cells, this is a busy landscape and requires specific education around patient characteristics, treatment selection, and toxicity management to provide the best treatment options for our patients.
Our sponsors:
More Information
This high-impact, three-hour educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engagers, and CAR T therapies among healthcare professionals.
At the conclusion of this educational activity, you will be able to:
- Understand the types of patients who should be considered for novel immune based strategies including bispecific T cell engagers and CAR T cell therapy.
- Understand the differences between TCEs, antibody drug conjugates, and CAR T cell process and data for appropriate care of the patient prior to consideration for these therapies.
- Understand toxicities and their management post-novel immune strategies.
